JP2010517998A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010517998A5 JP2010517998A5 JP2009548187A JP2009548187A JP2010517998A5 JP 2010517998 A5 JP2010517998 A5 JP 2010517998A5 JP 2009548187 A JP2009548187 A JP 2009548187A JP 2009548187 A JP2009548187 A JP 2009548187A JP 2010517998 A5 JP2010517998 A5 JP 2010517998A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- medicament
- pharmaceutically acceptable
- thiocyanate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 22
- 238000000034 method Methods 0.000 claims 14
- 238000006243 chemical reaction Methods 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical group CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical group CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims 3
- 230000000397 acetylating effect Effects 0.000 claims 3
- 150000002148 esters Chemical class 0.000 claims 3
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- ARXKVVRQIIOZGF-UHFFFAOYSA-N 1,2,4-butanetriol Chemical compound OCCC(O)CO ARXKVVRQIIOZGF-UHFFFAOYSA-N 0.000 claims 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical group N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 claims 2
- 239000002585 base Substances 0.000 claims 2
- 238000005341 cation exchange Methods 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims 1
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 claims 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims 1
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 108010015720 Dopamine beta-Hydroxylase Proteins 0.000 claims 1
- 102100033156 Dopamine beta-hydroxylase Human genes 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 1
- 229910052783 alkali metal Inorganic materials 0.000 claims 1
- -1 alkali metal thiocyanate Chemical class 0.000 claims 1
- 230000029936 alkylation Effects 0.000 claims 1
- 238000005804 alkylation reaction Methods 0.000 claims 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N anhydrous trimethylamine Natural products CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 229920001429 chelating resin Polymers 0.000 claims 1
- 229940125904 compound 1 Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229960003638 dopamine Drugs 0.000 claims 1
- 235000019253 formic acid Nutrition 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 230000033444 hydroxylation Effects 0.000 claims 1
- 238000005805 hydroxylation reaction Methods 0.000 claims 1
- 239000012442 inert solvent Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229960002748 norepinephrine Drugs 0.000 claims 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims 1
- 150000007524 organic acids Chemical class 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 claims 1
- 229940116357 potassium thiocyanate Drugs 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 238000006884 silylation reaction Methods 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- AGOSGCWATIJZHQ-UHFFFAOYSA-N tert-butyl [(2-methylpropan-2-yl)oxycarbonylamino] carbonate Chemical compound CC(C)(C)OC(=O)NOC(=O)OC(C)(C)C AGOSGCWATIJZHQ-UHFFFAOYSA-N 0.000 claims 1
- 0 C*CCC(N1[C@](Cc2cc(F)c3)COc2c3F)=CNC1=S Chemical compound C*CCC(N1[C@](Cc2cc(F)c3)COc2c3F)=CNC1=S 0.000 description 8
- DVGHKWZFOOHQHX-LLVKDONJSA-N ONCCC(N1[C@H](Cc2cc(F)c3)COc2c3F)=CNC1=S Chemical compound ONCCC(N1[C@H](Cc2cc(F)c3)COc2c3F)=CNC1=S DVGHKWZFOOHQHX-LLVKDONJSA-N 0.000 description 3
- XHYRRTFPWAZCND-UHFFFAOYSA-N CC(NCCC(N1CC(Cc2cc(F)c3)COc2c3F)=CNC1=S)=O Chemical compound CC(NCCC(N1CC(Cc2cc(F)c3)COc2c3F)=CNC1=S)=O XHYRRTFPWAZCND-UHFFFAOYSA-N 0.000 description 1
- ZYMJCPDCUHPWRB-CYBMUJFWSA-N CC(NCCC(N1[C@H](Cc2cc(F)c3)COc2c3F)=CNC1=S)=O Chemical compound CC(NCCC(N1[C@H](Cc2cc(F)c3)COc2c3F)=CNC1=S)=O ZYMJCPDCUHPWRB-CYBMUJFWSA-N 0.000 description 1
- YYEZYENJAMOWHW-UHFFFAOYSA-N CC1(C)OC(CCO)CO1 Chemical compound CC1(C)OC(CCO)CO1 YYEZYENJAMOWHW-UHFFFAOYSA-N 0.000 description 1
- CWWWTTYMUOYSQA-LLVKDONJSA-N NCCC(N1[C@H](Cc2cc(F)c3)COc2c3F)=CNC1=S Chemical compound NCCC(N1[C@H](Cc2cc(F)c3)COc2c3F)=CNC1=S CWWWTTYMUOYSQA-LLVKDONJSA-N 0.000 description 1
- DAYXRSGRECILGE-VIFPVBQESA-N ONCCC(N1C[C@H](C2)COc(c(F)c3)c2cc3F)=CNC1=S Chemical compound ONCCC(N1C[C@H](C2)COc(c(F)c3)c2cc3F)=CNC1=S DAYXRSGRECILGE-VIFPVBQESA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0701969A GB0701969D0 (en) | 2007-02-01 | 2007-02-01 | Compounds |
| GB0701968A GB0701968D0 (en) | 2007-02-01 | 2007-02-01 | Compounds |
| PCT/PT2008/000004 WO2008094054A2 (en) | 2007-02-01 | 2008-01-31 | 6, 8-dichlorchroman-3-yl-l, 3-dihydroimidazole-2-thione derivatives and their use for the treatment of cardiovascular disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010517998A JP2010517998A (ja) | 2010-05-27 |
| JP2010517998A5 true JP2010517998A5 (enExample) | 2011-03-24 |
Family
ID=39272441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009548187A Pending JP2010517998A (ja) | 2007-02-01 | 2008-01-31 | 化合物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20100093817A1 (enExample) |
| EP (1) | EP2121668A2 (enExample) |
| JP (1) | JP2010517998A (enExample) |
| AR (1) | AR065107A1 (enExample) |
| WO (1) | WO2008094054A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0701965D0 (en) * | 2007-02-01 | 2007-03-14 | Portela & Ca Sa | Process |
| US10072039B2 (en) | 2013-07-25 | 2018-09-11 | Scinopharm Taiwan, Ltd. | Process for the production of Fondaparinux sodium |
| CA2919206C (en) * | 2013-07-25 | 2018-09-25 | Scinopharm Taiwan, Ltd. | Process for the production of fondaparinux sodium |
| US20230183283A1 (en) * | 2016-10-14 | 2023-06-15 | Bonac Corporation | Novel glycoside compound and production method therefor |
| CN111333528B (zh) * | 2020-04-10 | 2022-10-21 | 苏州爱玛特生物科技有限公司 | 一种多构型o-苯基-丝氨酸类化合物的合成方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0757677B1 (en) * | 1994-04-26 | 2003-06-18 | Syntex (U.S.A.) LLC | Benzocyclohexylimidazolethione derivatives |
| US7125904B2 (en) * | 2002-10-11 | 2006-10-24 | Portela & C.A., S.A. | Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation |
-
2008
- 2008-01-31 WO PCT/PT2008/000004 patent/WO2008094054A2/en not_active Ceased
- 2008-01-31 EP EP08705174A patent/EP2121668A2/en not_active Withdrawn
- 2008-01-31 AR ARP080100395A patent/AR065107A1/es unknown
- 2008-01-31 US US12/524,940 patent/US20100093817A1/en not_active Abandoned
- 2008-01-31 JP JP2009548187A patent/JP2010517998A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5049013B2 (ja) | インドリン化合物およびその製造方法 | |
| CN101309917B (zh) | 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂 | |
| CN1080260C (zh) | 取代的吲哚衍生物以及它们作为iv型磷酸二酯酶(pde)和肿瘤坏死因子(tnf)抑制剂的用途 | |
| CN104520293B (zh) | 抗病毒化合物的合成 | |
| JP2010517998A5 (enExample) | ||
| JP6108112B2 (ja) | 改良されたルフィナミド調製プロセス | |
| JP2006508976A5 (ja) | ３−アミノ−ピペリジン誘導体及び製造法 | |
| JP2017521398A (ja) | 多環式カルバモイルピリドン化合物の合成 | |
| JP2006506368A5 (enExample) | ||
| JP2010526136A5 (enExample) | ||
| CN102702067B (zh) | 用于合成西洛多辛的中间体及其制备方法和用途 | |
| JP2008543860A5 (enExample) | ||
| TW201008916A (en) | 4,5-dihydro-oxazol-2-yl derivatives | |
| CN105985225A (zh) | 一种lcz-696及其中间体的制备方法 | |
| CN101039917A (zh) | 制备替米沙坦的方法 | |
| JP2011507941A5 (enExample) | ||
| JP2011506492A5 (enExample) | ||
| CN101939289A (zh) | 用于制备伏立诺他的新方法 | |
| JP2014520796A5 (enExample) | ||
| CN102219803A (zh) | 一种伊替米贝中间体的制备方法 | |
| CN1063487A (zh) | 苯氧基烷基羧酸衍生物及其制备方法 | |
| CA2775581A1 (en) | Processes for the preparation of 2-(1-phenylethyl)isoindolin-1-one compounds | |
| CN102731408A (zh) | 一种阿齐沙坦中间体及其制备方法 | |
| CN1091743A (zh) | 吡咯衍生物，其制备方法及其在治疗上的应用 | |
| CN102093254B (zh) | 一种二水合3-(2，2，2-三甲基肼)丙酸盐的制备方法 |